

Alan C Moss

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7266581/alan-c-moss-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126
papers

4,566
citations

41
h-index

63
g-index

140
ext. papers

5,239
ext. citations

5.1
avg, IF

5.86
L-index

#	Paper	IF	Citations
126	Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1552-1563	4.5	1
125	Implications of recurrent SARS-CoV-2 outbreaks for IBD management. <i>Frontline Gastroenterology</i> , 2021 , 12, 316-321	2.6	0
124	Modulation of lymphocyte-mediated tissue repair by rational design of heterocyclic aryl hydrocarbon receptor agonists. <i>Science Advances</i> , 2020 , 6, eaay8230	14.3	17
123	Mesalamine in the Initial Therapy of Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020 , 49, 689-704	4.4	2
122	Inflammatory Bowel Disease Environmental Risk Factors: Diet and Gut Microbiota. <i>Current Gastroenterology Reports</i> , 2020 , 22, 57	5	8
121	Dibutyl-phthalate exposure from mesalamine medications and serum thyroid hormones in men. <i>International Journal of Hygiene and Environmental Health</i> , 2019 , 222, 101-110	6.9	14
120	Role of Vitamin D in the Natural History of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 742-752	1.5	41
119	Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 913-921	6.1	22
118	Sexual Dysfunction in Men With Inflammatory Bowel Disease: A New IBD-Specific Scale. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 310-316	4.5	25
117	Higher serum vitamin D levels are associated with protective serum cytokine profiles in patients with ulcerative colitis. <i>Cytokine</i> , 2018 , 103, 38-45	4	22
116	A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and serum reproductive hormones in men. <i>Environmental Research</i> , 2018 , 160, 121-131	7.9	9
115	Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with solid organ transplants: an institutional experience and review of the literature. <i>Transplant Infectious Disease</i> , 2018 , 20, e12967	2.7	21
114	HIF-1 β induced xenobiotic transporters promote Th17 responses in Crohn's disease. <i>Journal of Autoimmunity</i> , 2018 , 94, 122-133	15.5	21
113	Vitamin D in inflammatory bowel disease: more than just a supplement. <i>Current Opinion in Gastroenterology</i> , 2018 , 34, 217-225	3	56
112	Knowledge Gaps in the Management of Postoperative Crohn's Disease: A US National Survey. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 53-60	4	3
111	Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 240-246.e1	6.9	70
110	Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 1113-1123	1.5	11

109	Purinergic signaling during intestinal inflammation. <i>Journal of Molecular Medicine</i> , 2017 , 95, 915-925	5.5	55
108	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1136-1137	6.9	
107	Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2017 , 86, 1006-1011.e8	5.2	47
106	Cutaneous Vasculitis in a Patient with Crohn's Disease Treated with Adalimumab. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, E1-E2	4.5	8
105	C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab. <i>Journal of Digestive Diseases</i> , 2017 , 18, 678-683	3.3	2
104	Bilirubin suppresses Th17 immunity in colitis by upregulating CD39. <i>JCI Insight</i> , 2017 , 2,	9.9	45
103	Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2017 , 23, 8082-8089	5.6	7
102	The Use and Efficacy of Fecal Microbiota Transplantation for Refractory Clostridium difficile in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 2704-2710	4.5	6
101	Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 2182-90	4.5	128
100	Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 619-25	1.5	66
99	Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2016 , 111, 685-90	0.7	101
98	P-108 Infliximab-Associated Suppression of Cytokine Release by Mucosal Explants Predicts Success of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, S43-S44	4.5	
97	Luminal Extracellular Vesicles (EVs) in Inflammatory Bowel Disease (IBD) Exhibit Proinflammatory Effects on Epithelial Cells and Macrophages. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1587-95	4.5	63
96	A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease. <i>Environment International</i> , 2016 , 95, 120-30	12.9	25
95	Crohn's disease stricture evaluation and management. <i>Techniques in Gastrointestinal Endoscopy</i> , 2016 , 18, 136-144	0.8	
94	The effects of responsible drinking messages on attentional allocation and drinking behaviour. <i>Addictive Behaviors</i> , 2015 , 44, 94-101	4.2	31
93	MR Enterography of the Ileoanal Pouch: Descriptive Radiologic Analysis With Endoscopic and Pathologic Correlation. <i>American Journal of Roentgenology</i> , 2015 , 205, W478-84	5.4	11
92	NADH oxidase-dependent CD39 expression by CD8(+) T cells modulates interferon gamma responses via generation of adenosine. <i>Nature Communications</i> , 2015 , 6, 8819	17.4	46

91	Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2806-14	4.5	37
90	Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2873-8	4.5	15
89	Iron Replacement in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1976-81	4.5	10
88	Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2562-9	4.5	24
87	Optimizing the use of biological therapy in patients with inflammatory bowel disease. <i>Gastroenterology Report</i> , 2015 , 3, 63-8	3.3	50
86	CD39 and CD161 modulate Th17 responses in Crohn's disease. <i>Journal of Immunology</i> , 2014 , 193, 3366-73	3.3	63
85	The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 940-8	6.1	9
84	A fatal case of diffuse enteritis after colectomy for ulcerative colitis: a case report and review of the literature. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1086-9	0.7	8
83	Characterization of circulating microparticle-associated CD39 family ecto-nucleotidases in human plasma. <i>Purinergic Signalling</i> , 2014 , 10, 611-8	3.8	20
82	True costs of infliximab testing and administration. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 346	6.9	
81	Prevention of post-operative recurrence of Crohn's disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 1147-54	5.6	40
80	Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis. <i>Journal of Managed Care Pharmacy</i> , 2014 , 20, 309-14		10
79	Current and emerging maintenance therapies for ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 359-68	4.2	5
78	Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. <i>The Cochrane Library</i> , 2014 , CD005046	5.2	28
77	Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1850-5	0.7	17
76	Rifaximin suppresses background intestinal 18F-FDG uptake on PET/CT scans. <i>Nuclear Medicine Communications</i> , 2014 , 35, 1026-31	1.6	9
75	Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 1-6	4.5	111
74	Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis. <i>Journal of Clinical Gastroenterology</i> , 2014 , 48, 351-5	3	8

73	Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 1996-2003	4.5	157
72	The meaning of low-grade inflammation in clinically quiescent inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2014 , 30, 365-9	3	13
71	The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 545-52	4.5	73
70	Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 856-60	4.5	49
69	Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease. <i>PLoS ONE</i> , 2014 , 9, e87956	3.7	43
68	Comment on Moshkovska et al. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, E19	4.5	1
67	Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 991-6	6.9	87
66	Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. <i>American Journal of Gastroenterology</i> , 2013 , 108, 40-7; quiz 48	0.7	256
65	Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. <i>Cellular Immunology</i> , 2013 , 282, 66-70	4.4	26
64	The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 786-94	6.1	78
63	A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. <i>American Journal of Gastroenterology</i> , 2013 , 108, 249-55	0.7	16
62	Prevalence and lifetime risk of endoscopy-related complications among patients with inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 1288-93	6.9	14
61	Lectin-reactive anti-IgA in patients with Crohn's disease: correlation with clinical phenotypes. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 2796-800	4.5	1
60	Commentary: impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 843	6.1	4
59	Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 1188-97	6.1	61
58	Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 460-6	6.1	88
57	Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 779-84	4.5	61
56	Prevention of postoperative recurrence of Crohn's disease: what does the evidence support?. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 856-9	4.5	19

55	CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. <i>European Journal of Immunology</i> , 2012 , 42, 3062-72	6.1	45
54	Commentary: outcomes after escalation of infliximab in moderately active ulcerative colitis □ author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 958-959	6.1	
53	Open conformation tissue transglutaminase testing for celiac dietary assessment. <i>Digestive and Liver Disease</i> , 2012 , 44, 375-8	3.3	9
52	Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 691-6	4.5	32
51	Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1057-63	4.5	38
50	Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1608-16	4.5	32
49	Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 562-7	6.1	36
48	5-aminosalicylates to prevent relapse of Crohn's disease after surgery. <i>American Journal of Gastroenterology</i> , 2012 , 107, 487; author reply 487-8	0.7	
47	Curcumin for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2012 , 10, CD008424	5.2	21
46	Mesalamine in the treatment and maintenance of remission of ulcerative colitis. <i>Expert Review of Clinical Pharmacology</i> , 2012 , 5, 113-23	3.8	74
45	Focal physiologic fluorodeoxyglucose activity in the gastrointestinal tract is located within the colonic lumen. <i>Nuclear Medicine Communications</i> , 2012 , 33, 641-7	1.6	7
44	Capsule endoscopy for small-bowel evaluation in Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2011 , 74, 167-75	5.2	47
43	Cyclosporine is safe and effective in patients with severe ulcerative colitis. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 107-12	3	45
42	Treg CD39 expression as a modulator of intestinal inflammation in Crohn's DiseaseP-240.. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, S83	4.5	
41	Efficacy of Curcumin (turmeric) in the treatment of Inflammatory Bowel Disease: A systematic reviewP-15.. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, S16	4.5	
40	Development of a repeated measures affective change blindness task. <i>Behavior Research Methods</i> , 2011 , 43, 826-33	6.1	2
39	Drug development in inflammatory bowel disease: the role of the FDA. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 2585-93	4.5	10
38	Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 802-9	6.1	62

37	Once-daily mesalamine granules for ulcerative colitis. <i>Expert Review of Clinical Immunology</i> , 2010 , 6, 521-5	6.1	7
36	Capsule endoscopy in suspected Crohn's disease: "yield" does not equal "diagnosis". <i>American Journal of Gastroenterology</i> , 2010 , 105, 2111; author reply 2111-2	0.7	11
35	Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 171-5	1.5	23
34	Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 1413-20	4	17
33	Adalimumab for cutaneous metastatic Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 723-4	4.5	10
32	Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1393-6	4.5	32
31	Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander?. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1620-7	4.5	177
30	SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 274-83	12.9	44
29	Interventions for prevention of post-operative recurrence of Crohn's disease. <i>The Cochrane Library</i> , 2009 , CD006873	5.2	99
28	The utility of capsule endoscopy in patients with suspected Crohn's disease. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2734-9	0.7	89
27	Pseudogout after polyethylene glycol bowel cleansing. <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 95-6	3	3
26	The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 221-7	6.1	31
25	Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. <i>Drugs</i> , 2008 , 68, 1089-103	12.1	24
24	Steroid-refractory severe ulcerative colitis: what are the available treatment options?. <i>Drugs</i> , 2008 , 68, 1157-67	12.1	18
23	Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis. <i>American Journal of Pathology</i> , 2008 , 173, 400-10	5.8	32
22	Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1121-6	5.9	38
21	Melanin-concentrating hormone as a mediator of intestinal inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 10613-8	11.5	52
20	The risks and the benefits of mesalazine as a treatment for ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2007 , 6, 99-107	4.1	35

19	Gastrointestinal [corrected] stromal tumor of the ampulla of vater mimicking a duodenal ulcer. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, A26	6.9	2
18	In silico gene expression analysis--an overview. <i>Molecular Cancer</i> , 2007 , 6, 50	42.1	34
17	Reducing the torment of diarrhea: tormentil for active ulcerative colitis. <i>Journal of Clinical Gastroenterology</i> , 2007 , 41, 797-8	3	7
16	Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. <i>Gut</i> , 2007 , 56, 1210-7	19.2	57
15	Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. <i>European Journal of Gastroenterology and Hepatology</i> , 2007 , 19, 1119-24	2.2	146
14	Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. <i>Cancer Treatment Reviews</i> , 2007 , 33, 213-21	14.4	174
13	Curcumin for maintenance therapy in ulcerative colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 642; author reply 642	6.9	5
12	Reflux, dyspepsia, and disorders of the foregut. <i>Southern Medical Journal</i> , 2007 , 100, 266-72; quiz 273, 294	0.6	1
11	Combined oral and topical mesalazine treatment for extensive ulcerative colitis. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006 , 3, 290-3		4
10	Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. <i>Journal of Immunology</i> , 2006 , 177, 3355-61	5.3	87
9	Net1 and Myeov: computationally identified mediators of gastric cancer. <i>British Journal of Cancer</i> , 2006 , 94, 1204-12	8.7	50
8	ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 345, 216-21	3.4	35
7	Palliative biliary stents for obstructing pancreatic carcinoma. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD004200		122
6	Palliative biliary stents for obstructing pancreatic carcinoma. <i>The Cochrane Library</i> , 2006 , CD004200	5.2	30
5	Thyroid cancer and Crohn's disease: association or coincidence?. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 79-80	4.5	5
4	Attitudes to peer review as a competence assurance structure--results of a survey of Irish physicians. <i>Irish Journal of Medical Science</i> , 2005 , 174, 43-6	1.9	
3	Colonic surveillance by CT colonography using axial images only. <i>European Radiology</i> , 2004 , 14, 763-7	8	15
2	Efficacy of IV Buscopan as a muscle relaxant in CT colonography. <i>European Radiology</i> , 2003 , 13, 2264-70	8	57

1 Clinical results of CT colonoscopy. *European Radiology*, **2001**, 11, 2188-94

8 26